References for the retatrutide data: Jastreboff et al., NEJM 2023: Sanyal et al., Nature Medicine 2024: Giblin et al., TRIUMPH rationale, Diabetes Obesity Metabolism 2025: How to Minimize Side Effects and Maximize Comfort GLP-1s can cause nausea, constipation, and appetite suppression
Postpartum GLP-1 Therapy and Personalized Genetic Testing After pregnancy and weaning from breastfeeding, many women find that semaglutide, tirzepatide, or combination compounds help restore weight management progress lost during discontinuation
This selectivity of the blood vessels acts as a barrier- called the blood-brain barrier
Northern Territory Government
Evidence Trials investigating the use of GLP-1 RAs currently approved in the United States in addition to basal insulin versus an active comparator of prandial insulin are summarized in TABLE 2